About Focus Pharmaceuticals
Focus Pharmaceuticals is a Healthcare company based in London (United Kingdom) founded in 2002, and was acquired by Amdipharm Mercury in October 2014. Geospatial data and aerial imagery services are provided globally. Its chief executive, as recorded, is Mark Cresswell. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Provider of geospatial data and aerial imagery services. This includes aerial photography, scan services for analog images, and aerotriangulation. They also create and process geospatial data, offering orthophotos, topographic maps, 3D terrain models derived from aerial or laser scan data, and 3D city models. Further services encompass specialized geospatial data such as green space inventories, property records with outdoor facilities, and solar potential analyses based on 3D models or laser scan data. WebGIS solutions for data visualization and analysis are also provided.
- Headquarters London, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website focuspharmaceuticals.co.uk
- Social LinkedIn X
- Acquired by Amdipharm Mercury (Oct 2014)
- Investors
- Acquired byAmdipharm Mercury
(Oct 2014)
Investors in Focus Pharmaceuticals
Focus Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Amdipharm Mercury.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A diversified portfolio of off-patent drugs is provided. | 2013 | amcolimited.com | London, United Kingdom |
Investor details for Focus Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Focus Pharmaceuticals
1 people are tracked at Focus Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Mark Cresswell | CEO & MD | Leadership |
Complete people profiles for Focus Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Focus Pharmaceuticals
2 dated milestones of Focus Pharmaceuticals across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Focus Pharmaceuticals is founded.
- Exit Acquired by Amdipharm Mercury.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Focus Pharmaceuticals
Focus Pharmaceuticals was founded in 2002.
Focus Pharmaceuticals is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Mark Cresswell is the CEO of Focus Pharmaceuticals, as recorded in our data.
Provider of geospatial data and aerial imagery services. This includes aerial photography, scan services for analog images, and aerotriangulation. They also create and process geospatial data, offering orthophotos, topographic maps, 3D terrain models derived from aerial or laser scan data, and 3D city models. Further services encompass specialized geospatial data such as green space inventories, property records with outdoor facilities, and solar potential analyses based on 3D models or laser scan data. WebGIS solutions for data visualization and analysis are also provided.
Focus Pharmaceuticals has 1 investor. Key investors include Amdipharm Mercury.
Yes. Focus Pharmaceuticals was acquired by Amdipharm Mercury in October 2014.